A share price of Gilead Sciences, Inc. [GILD] is currently trading at $73.66, up 1.42%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GILD shares have gain 2.16% over the last week, with a monthly amount drifted -5.22%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities. In a post published today on Yahoo Finance, – New Data Evaluating the Efficacy and Safety Profile of Biktarvy for the Treatment of People with HIV and Hepatitis B or Tuberculosis will be Presented –.
From an analyst’s perspective:
Gilead Sciences, Inc. [NASDAQ: GILD] stock has seen the most recent analyst activity on February 22, 2024, when Truist downgraded its rating to a Hold and also revised its price target to $82 from $91. Previously, Deutsche Bank started tracking the stock with Hold rating on November 09, 2023, and set its price target to $75. On September 08, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $95 on the stock. HSBC Securities started tracking the stock assigning a Reduce rating and suggested a price target of $71 on September 06, 2023. Barclays reiterated its recommendation of a Equal Weight and reduced its price target to $80 on July 24, 2023. BMO Capital Markets upgraded its rating to Outperform for this stock on May 16, 2023, and upped its price target to $100.
Gilead Sciences, Inc. experienced fluctuations in its stock price throughout the past year between $71.37 and $87.86. Currently, Wall Street analysts expect the stock to reach $79.25 within the next 12 months. Gilead Sciences, Inc. [NASDAQ: GILD] shares were valued at $73.66 at the most recent close of the market. An investor can expect a potential return of 7.59% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Trailing Twelve Months sales for Gilead Sciences, Inc. [NASDAQ:GILD] were 27.06B which represents -2.75% decline. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.21%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.26 and Total Capital is 0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 72.87 points at the first support level, and at 72.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 74.27, and for the 2nd resistance point, it is at 74.87.
Gilead Sciences, Inc. [GILD] reported earnings per share of $1.72 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.76/share, meaning a difference of -$0.04 and a surprise factor of -2.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $2.29 per share as compared to estimates of $1.92 per share, a difference of $0.37 representing a surprise of 19.30%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Gilead Sciences, Inc. [NASDAQ:GILD] is 1.43. Also, the Quick Ratio is 1.27, while the Cash Ratio stands at 0.54. Considering the valuation of this stock, the price to sales ratio is 3.39, the price to book ratio is 4.02 and price to earnings (TTM) ratio is 16.36.
Transactions by insiders
Recent insider trading involved Parsey Merdad, Chief Medical Officer, that happened on Feb 29 ’24 when 8230.0 shares were sold. Chief Medical Officer, Parsey Merdad completed a deal on Feb 28 ’24 to sell 2000.0 shares. Meanwhile, 10% Owner GILEAD SCIENCES, INC. bought 0.91 million shares on Feb 12 ’24.
